Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Stock Leaps 24.18 Percent on News of ParAllele Collaboration

NEW YORK, April 6 (GenomeWeb News) - Shares in Genaissance Pharmaceuticals were up 24.18 percent, or $.30, at $1.52 in mid-afternoon trading after the company said it and ParAllele BioScience would co-market ParAllele's upcoming MegAllele DME-T assay panel.

 

Under the terms of the agreement, ParAllele will license more than 400 proprietary SNPs from Genaissance. These will be combined with SNPs from the public domain to make up a total of around 1,500 SNPs that ParAllele will incorporate into MegAllele DME-T, which will assay around 160 genes involved in drug metabolism and transport pathways.

 

Genaissance will market the panel for research use only in GLP-compliant environments.

 

In mid-March, ParAllele said that it had  teamed with Eli Lilly to make the DME-T panel available for contract research organizations to genotype Lilly's clinical trial participants. This application for the assay panel is expected to be available by August or September.

 

ParAllele also said at the time that it would file for FDA approval to market a version of the assay as an in vitro diagnostic.

 

The panel will run on Affymetrix's GeneChip platform.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.